Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R. Srinivasan R, et al. Among authors: shalabi r. Br J Haematol. 2004 Mar;124(6):777-86. doi: 10.1111/j.1365-2141.2004.04856.x. Br J Haematol. 2004. PMID: 15009066 Free article.
Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.
McDuffee E, Aue G, Cook L, Ramos-Delgado C, Shalabi R, Worthy T, Vo P, Childs RW. McDuffee E, et al. Among authors: shalabi r. Bone Marrow Transplant. 2017 May;52(5):759-761. doi: 10.1038/bmt.2016.346. Epub 2017 Jan 9. Bone Marrow Transplant. 2017. PMID: 28067871 Free PMC article. No abstract available.
Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.
Purev E, Tian X, Aue G, Pantin J, Vo P, Shalabi R, Reger RN, Cook L, Ramos C, Cho E, Worthy T, Khuu H, Stroncek D, Young NS, Childs RW. Purev E, et al. Among authors: shalabi r. Br J Haematol. 2017 Mar;176(6):950-960. doi: 10.1111/bjh.14448. Epub 2017 Feb 7. Br J Haematol. 2017. PMID: 28169418 Free PMC article. Clinical Trial.
A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R. Vo P, et al. Among authors: shalabi r. Br J Haematol. 2020 May;189(3):551-558. doi: 10.1111/bjh.16385. Epub 2020 Feb 21. Br J Haematol. 2020. PMID: 32086819 Free PMC article.
Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation.
Vo P, Srinivasan R, Purev E, McDuffee E, Worthy T, Shalabi R, Wood K, Wells B, Reger R, Stroncek D, Geller N, Aue G, Tian X, Childs R. Vo P, et al. Among authors: shalabi r. Bone Marrow Transplant. 2024 Dec;59(12):1777-1779. doi: 10.1038/s41409-024-02380-6. Epub 2024 Sep 9. Bone Marrow Transplant. 2024. PMID: 39251835 Free PMC article. No abstract available.
27 results